Recently, it has been shown that enzyme encapsulation inside metal–organic frameworks (MOFs) can increase enzyme activity and serve as protection from adverse environmental conditions. Little is understood about how the enzymes move into and are held inside the MOFs although it is believed that intermolecular forces between the MOF and the enzyme cause it to be held in place. If this process can be better understood, it can have dramatic implications on the cost-effectiveness and implementation of enzyme–MOF complexes. This is of specific importance in the medical sector for protein therapy and the industrial sector where enzyme use is expected to increase. Herein, we synthesized alcohol dehydrogenase (ADH) and PCN-333 to study encapsulation, stability, and enzyme activity to expand the knowledge of our field and offer a potential improvement to a synthetic route for biofuel synthesis. From this, we found a correlation between the concentration of a buffer and the loading of an enzyme, with surprising loading trends. We conclude that the buffer solution decreases interactions between the enzyme and MOF, supporting conventional theory and allowing it to penetrate deeper into the structure causing higher enzyme loading while allowing for excellent stability over time at various pH values and temperatures and after multiple reactions. We also observe new trends such as a rebounding effect in loading and “out-of-bounds” reactions.

A series of 2-deoxy-2-iodo-α-d-mannopyranosylbenzotriazoles was synthesized using the benzyl, 4,6-benzylidene and acetyl protected D-glucal in the presence of N-iodosuccinimide (NIS). Subsequent removal of the iodine at the C-2 position using tributyltin hydride under free radical conditions afforded the 2-deoxy-α-d-glucopyranosylbenzotriazoles in moderate to high yields. This method was extended to the preparation of substituted 2-deoxy-β-d-glucopyranosylimidazoles as well. The stereoselectivity of the addition reaction and the effect of the protecting group and temperature on anomer distribution of the benzotriazole series were also investigated. The anticancer properties of the newly synthesized compounds were evaluated in a series of viability studies using HeLa (human cervical adenocarcinoma), human breast and lung cancer cell lines. The N-[3,4,6-tri-O-benzyl-2-deoxy-α-d-glucopyranosyl]-1H-benzotriazole and the N-[3,4,6-tri-O-acetyl-2-deoxy-α-d-glucopyranosyl]-2H-benzotriazole were found to be the most potent cancer cell inhibitors at 20 µM concentrations across all four cell lines.